The Consensus Panel 3 (CP3) of the 12th International Workshop on Waldenström macroglobulinemia (IWWM-12) has reviewed and incorporated current data to make recommendations for the management of patients with high-risk WM (HR-WM). The report can be read here.
Connection to others with Waldenstrom's Macroglobulinemia is crucial when you're diagnosed with this rare cancer. Only those with your disease can truly understand what you're going through. Connect to WaldenFriends around the world in our spring newsletter, right here.
Clinical trial NCT05006716 of Beigene’s BGB-16673, a Bruton Tyrosine Kinase Targeted Protein Degrader, is recruiting patients in Calgary, Edmonton, Québec, Vancouver, and Toronto. Official title of the study: A Phase 1/2, Open-Label, Dose Escalation and Expansion Study of the Bruton Tyrosine Kinases Targeted Protein Degrader BGB-16673 in Patients with B-cell Malignancies. For more information, see the trial's description on the NIH website.
Two journal article provide an end-to-end review of WM. Co-authored by experts from the Dana-Farber Cancer Institute, they are highly recommended to all practitioners. Part 1: Epidemiology, Pathogenesis, Clinicopathologic Characteristics, Differential Diagnosis, Risk Stratification, and Clinical Problems is available at https://www.mjhid.org/mjhid/article/view/5732/4535 Part 2: Focus on Therapy is available at https://www.mjhid.org/mjhid/article/view/5878/4639
Canadians with Waldenström’s Macroglobulinemia who meet inclusion requirements may want to consider participation in a new study of Beigene’s BGB-16673, a Bruton Tyrosine Kinase Targeted Protein Degrader. To help in your understanding of a BTK Degrader, see our recent post comparing them to BTK inhibitors (BTKi). Official title of the study: A Phase 1/2, Open-Label, Dose Escalation and Expansion Study of the Bruton Tyrosine Kinases Targeted Protein Degrader BGB-16673 in Patients with B-cell Malignancies. Canadian Study Locations Now Recruiting: Calgary, AB: Arthur Child Comprehensive Cancer Centre Edmonton, AB: Cross Cancer Institute Québec, QC: Université de Laval, Hôpital de l’enfant Jésus, Centre Integre de Cancerologie Vancouver, [...]
Bruton’s tyrosine kinase (BTK) inhibitors and BTK Degraders are two different approaches to targeting BTK, a key enzyme in the B-cell receptor signaling pathway, which is crucial for the survival and proliferation of B-cells. Both strategies are used in the treatment of B-cell malignancies and autoimmune diseases, but they operate through distinct mechanisms. BTK Inhibitors Mechanism of Action: Inhibition. BTK inhibitors are small molecules that bind to the active site of BTK, preventing its phosphorylation (a biological reaction in which phosphate is added to an organic molecule) and subsequent activation. This inhibits downstream signaling pathways that are essential for B-cell proliferation [...]
All our doctors agree -- Quality of Life is so important to WMers! Learn in our winter newsletter about resources available to you that can improve your Quality of Life: Look at what the Research shows Check out the IWMF Wellness Program -- a magnificent resource Meet Others Who Have Improved their Quality of Life Seek and Find Community Support Manage the Side-effects of Treatment with Good Nutrition Happy reading!
From the science desk, a report on: The 12th International Workshop on Waldenström’s Macroglobulinemia (IWWM-12) that took place in Prague, Czech Republic from October 17-19, 2024 where leading experts gathered to discuss the latest advances in the understanding and treatment of WM, and The 66th annual meeting and exposition of the American Society of Hematology (ASH) that took place in San Diego, California from December 7-10, 2024. The WMFC reviewed all of the IWWM-12 abstracts submitted in Prague and found that very many of the presentations/posters simply confirmed the work of others. For example, several abstracts confirmed three WM lineages: B [...]
The WMFC was delighted to be able to bring you Dr. Shirley D'Sa from University College London (UK) Hospitals. She presented to us on Friday Nov. 15th, 2024. Dr. D'Sa discussed two topics: Peripheral Neuropathy (PN), a common condition experienced by people with WM. Bing-Neel Syndrome, a less-common complication of WM. For both of these, Dr. D'Sa addressed the symptoms of these conditions, how they develop, how you can enable a swift and accurate diagnosis and how it is recommended to treat these conditions. We came away understanding that Peripheral Neuropathy is far more complex than one might have thought and [...]
There have been changes in "the cloud" world recently, out of our control. We're told that Google and other email organizations are tightening up their email filtering rules. So emails from your WMFC might be ending up in your Junk or Spam email folders. And we hope you don't think they are either Junk or Spam! So please check your Junk and/or Spam folders to see if any recent emails from the WMFC have ended up in there. If so, there might be some settings you can change so that email from any address ending in @wmfc.ca is not to be [...]
